Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Free Cash Flow (2016 - 2026)

Akebia Therapeutics has reported Free Cash Flow over the past 10 years, most recently at $31.1 million for Q4 2025.

  • Quarterly Free Cash Flow rose 795.14% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.7 million through Dec 2025, up 266.37% year-over-year, with the annual reading at $67.7 million for FY2025, 266.37% up from the prior year.
  • Free Cash Flow was $31.1 million for Q4 2025 at Akebia Therapeutics, up from $28.0 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $33.8 million in Q3 2022 and troughed at -$70.8 million in Q1 2021.
  • The 5-year median for Free Cash Flow is -$11.8 million (2024), against an average of -$16.1 million.
  • Year-over-year, Free Cash Flow tumbled 378.18% in 2024 and then surged 795.14% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$62.8 million in 2021, then rose by 12.94% to -$54.7 million in 2022, then surged by 95.78% to -$2.3 million in 2023, then tumbled by 93.59% to -$4.5 million in 2024, then surged by 795.14% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Free Cash Flow are $31.1 million (Q4 2025), $28.0 million (Q3 2025), and $22.2 million (Q2 2025).